GMP REPROPOSAL IS NEEDED BEFORE REGULATION IS FINALIZED
This article was originally published in The Gray Sheet
Executive Summary
GMP REPROPOSAL IS NEEDED BEFORE REGULATION IS FINALIZED, the Health Industry Manufacturers Association argued in a Sept. 8 letter to FDA. "Before promulgating a new [good manufacturing practices regulation], the agency should issue at least one additional role that would have the status of a proposed rule and would permit further comment," HIMA suggested.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.